No Data
No Data
Express News | Briacell Initiates Patient Enrollment in First-in-Human Study of Bria-Ots™ in Advanced Metastatic Breast Cancer
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnol
Express News | BriaCell Therapeutics Announces Clinical Supply Agreement With BeiGene To Evaluate Safety And Efficacy Of Bria-OTS, BriaCell's Next Generation Immunotherapy
Express News | Briacell Announces Clinical Supply Agreement With Beigene for Bria-Ots™ First in Human Study
BriaCell Announces Clinical Supply Agreement With BeiGene for Bria-OTS First in Human Study
Study to evaluate the effects of Bria-OTS in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
83% intracranial objective response rate (iORR) with Bria-IMT in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC resistant
No Data